Barlow Wealth Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.16M Hold
4,334
– – 0.12% 53
2026
Q2
$1.1M Buy
4,334
+692
+19% +$149K 0.12% 57
2026
Q1
$759K Hold
3,642
– – 0.08% 67
2025
Q4
$802K Buy
3,642
+67
+2% +$15.3K 0.09% 67
2025
Q3
$818K Sell
3,575
-24
-0.7% -$4.89K 0.09% 64
2025
Q2
$687K Buy
3,599
+100
+3% +$18.6K 0.08% 68
2025
Q1
$651K Buy
3,499
+100
+3% +$19.4K 0.09% 68
2024
Q4
$582K Sell
3,399
-826
-20% -$152K 0.07% 76
2024
Q3
$818K Hold
4,225
– – 0.11% 70
2024
Q2
$744K Hold
4,225
– – 0.1% 73
2024
Q1
$686K Sell
4,225
-4
-0.1% -$689 0.09% 76
2023
Q4
$655K Buy
+4,229
New +$617K 0.09% 77

Other funds holding ABBV

Barlow Wealth Partners's ABBV Position: Q3 2026 in Review

Barlow Wealth Partners held its AbbVie (ABBV) position steady in Q3 2026 at 4,334 shares worth $1.16M. The position accounts for 0.12% of the portfolio, ranked #53.

Barlow Wealth Partners first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. 2,709 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Barlow Wealth Partners held 4,334 shares of AbbVie worth $1.16M as of Q3 2026.
  • Barlow Wealth Partners left its AbbVie share count unchanged in Q3 2026.
  • AbbVie made up 0.12% of Barlow Wealth Partners's portfolio in Q3 2026, its #53 holding.
  • Barlow Wealth Partners first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
  • 2,709 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Barlow Wealth Partners's 13F filing for Q3 2026, filed 15 Oct 2026.